Thanks for your interest in our recent Keyway TCR mimic Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:
1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target
Upon filling out this form, you will receive an email with a link to the webinar recording.
Keyway™ TCR Discovery is the first and only fully integrated discovery service for soluble therapeutics against peptide-MHCs. Keyway has developed a proprietary platform that you can access through our Discovery Services for TCRm today and engineered TCRs by the end of 2023. Keyway TCRm encompasses proprietary antibody-like bispecific formats for simultaneous effector cell engagement and target engagement.
To access this content, fill out the form below.
